Breaking News Instant updates and real-time market news.

OMER

Omeros

$16.17

0.32 (2.02%)

07:58
11/04/19
11/04
07:58
11/04/19
07:58

Omeros publishes results showing Omidria reduces fetanyl use in cataract surgery

Omeros announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug Omidria reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published in the peer-reviewed journal Clinical Ophthalmology. Omidria is approved by FDA for prevention of miosis and for reduction in postoperative pain for adults and pediatric patients undergoing cataract or lens replacement surgery. The study objectives were to evaluate the effect of Omidria compared to epinephrine on perioperative fentanyl use and pain in patients undergoing cataract surgery. Sixty patients were prospectively assigned to have either Omidria or epinephrine added to the irrigation solution used during surgery. Patients in the Omidria group were 6.7 times more likely not to require fentanyl, with 9.8% of Omidria patients requiring fentanyl versus 42.1% of epinephrine patients. In addition, mean visual analog scale pain scores were significantly lower in the Omidria group than in the epinephrine group. The proportion of patients with VAS scores of 3 was significantly greater in the Omidria group than in the epinephrine group. Omidria patients also were 94% less likely to require fentanyl or to have moderate-to-severe pain than patients receiving epinephrine. Congress and CMS understand the public health risk associated with opioid exposure and CMS is required under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment, or SUPPORT, for Patients and Communities Act to review payments under its outpatient prospective payment system for opioids and evidence-based non-opioid alternatives for pain management with a goal of ensuring that there are not financial incentives to use opioids instead of non-opioid alternatives. In its 2020 OPPS final rule published on November 1, CMS did not add any products to the non-opioid exclusion from packaged payment. Although CMS had received an analysis of the Donnenfeld data, CMS specifically requested peer-reviewed published evidence and the Donnenfeld study had not yet been published at the time the final rule was issued. With the publication of the Donnenfeld opioid-sparing data, Omeros believes that Omidria meets all of CMS' requirements for the non-opioid exclusion. CMS stated in the final rule that it will continue to analyze the evidence in support of the benefits of Omidria and monitor utilization of this drug, and Omeros intends to address CMS' Omidria-related comments. Omeros also plans to continue its administrative and legislative efforts to secure ongoing separate payment for Omidria beyond the drug's current pass-through extension. Omidria continues to receive separate payment from CMS under its pass-through extension until October 1, 2020.

  • 07

    Dec

OMER Omeros
$16.17

0.32 (2.02%)

05/06/19
CANT
05/06/19
INITIATION
CANT
Overweight
Omeros initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Omeros with an Outperform and $26 price target.
05/06/19
CANT
05/06/19
INITIATION
Target $26
CANT
Overweight
Omeros initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Omeros with an Overweight rating and $26 price target. The analyst believes investors can be rewarded from current levels through the company's pipeline alone. As such, the risk/reward is to the upside, "creating a compelling investment opportunity," Folkes tells investors in a research note.
05/06/19
05/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PagerDuty (PD) initiated with an Overweight at Piper Jaffray, with a Neutral at BTIG, with an Outperform at William Blair, with an Overweight at JPMorgan, with a Sector Weight at KeyBanc, with an Equal Weight at Morgan Stanley and with a Sector Perform at RBC Capital. 2. Tufin (TUFN) initiated with a Buy at Jefferies, with an Overweight at Piper Jaffray, with a Market Perform at William Blair, with a Hold at Stifel, with an Outperform at Oppenheimer, with an Overweight at JPMorgan and with an Overweight at Barclay. 3. Aclaris Therapeutics (ACRS) initiated with an Outperform at SVB Leerink. 4. Jumia Technologies (JMIA) initiated with a Neutral at Citi and with a Sector Perform at RBC Capital. 5. Omeros (OMER) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MOR

MorphoSys

$34.60

0.76 (2.25%)

14:27
12/10/19
12/10
14:27
12/10/19
14:27
Recommendations
MorphoSys analyst commentary  »

MorphoSys sounds close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEP

American Electric

$91.94

0.045 (0.05%)

14:23
12/10/19
12/10
14:23
12/10/19
14:23
Hot Stocks
PSO reaches settlement pact with Public Utility Division Staff of OCC »

Public Service Company of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CORV

Correvio

$1.39

(0.00%)

14:22
12/10/19
12/10
14:22
12/10/19
14:22
Periodicals
FDA panel said to vote against recommending approval for Correvio's Brinavess »

SAC Tracker, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

14:20
12/10/19
12/10
14:20
12/10/19
14:20
General news
The Europe Brief: »

The Europe Brief:…

EVH

Evolent Health

$9.02

1.125 (14.25%)

14:17
12/10/19
12/10
14:17
12/10/19
14:17
Recommendations
Evolent Health analyst commentary  »

William Blair says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/10/19
12/10
14:17
12/10/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/10/19
12/10
14:16
12/10/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$14.09

-6.42 (-31.30%)

14:03
12/10/19
12/10
14:03
12/10/19
14:03
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

CONN

Conn's

$14.08

-6.43 (-31.35%)

13:59
12/10/19
12/10
13:59
12/10/19
13:59
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

EVH

Evolent Health

$8.46

0.565 (7.16%)

13:59
12/10/19
12/10
13:59
12/10/19
13:59
Periodicals
Kentucky committee rejects outgoing governor's 'snub' of Evolent, LBF says »

The Government Contract…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDR

UDR, Inc.

$47.78

-0.11 (-0.23%)

13:56
12/10/19
12/10
13:56
12/10/19
13:56
Conference/Events
UDR, Inc. management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

XOM

Exxon Mobil

$68.73

-0.93 (-1.34%)

13:54
12/10/19
12/10
13:54
12/10/19
13:54
Hot Stocks
Exxon: Ruling affirms position company has held throughout 'baseless' probe »

ExxonMobil issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ADPT

Adaptive Biotechnologies

$29.09

-0.21 (-0.72%)

13:54
12/10/19
12/10
13:54
12/10/19
13:54
Conference/Events
Adaptive Biotechnologies management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVGO

Livongo Health

$25.83

-1.57 (-5.73%)

13:52
12/10/19
12/10
13:52
12/10/19
13:52
Recommendations
Livongo Health analyst commentary  »

Livongo Health valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WDFC

WD-40

$194.62

-1.12 (-0.57%)

13:51
12/10/19
12/10
13:51
12/10/19
13:51
Hot Stocks
WD-40 increases quarterly dividend nearly 10% »

WD-40 Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
12/10/19
12/10
13:50
12/10/19
13:50
General news
Treasury Action: the Treasury market is unmoved »

Treasury Action: the…

13:49
12/10/19
12/10
13:49
12/10/19
13:49
Conference/Events
JPMorgan consumer finance analyst to hold analyst/industry conference call »

Specialty & Consumer…

EVH

Evolent Health

$8.27

0.375 (4.75%)

13:49
12/10/19
12/10
13:49
12/10/19
13:49
Hot Stocks
Evolent Health jumps $1.55, or 20%, to $9.42 »

Contacts tell The Fly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
12/10/19
12/10
13:45
12/10/19
13:45
Conference/Events
JPMorgan semiconductors anayst to hold an analyst/industry conference call »

Semiconductors,…

NFLX

Netflix

$297.38

-5.1 (-1.69%)

13:45
12/10/19
12/10
13:45
12/10/19
13:45
Hot Stocks
Netflix says 'really proud' of animation work, cadence of films picking up »

Speaking at the UBS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

13:41
12/10/19
12/10
13:41
12/10/19
13:41
Conference/Events
JPMorgan restaurants analyst to hold an analyst/industry conference call »

Restaurants Analyst…

VALE

Vale

$12.35

-0.035 (-0.28%)

13:33
12/10/19
12/10
13:33
12/10/19
13:33
Conference/Events
Morgan Stanley materials analyst holds an analyst/industry conference call »

Head of Australia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$14.24

0.075 (0.53%)

13:33
12/10/19
12/10
13:33
12/10/19
13:33
Hot Stocks
CenturyLink pays Washington $6.1M to settle hidden fees lawsuit »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CI

Cigna

$190.30

-5.59 (-2.85%)

, MET

MetLife

$49.25

-0.315 (-0.64%)

13:31
12/10/19
12/10
13:31
12/10/19
13:31
Periodicals
New York Life in talks to buy nonmedical insurance unit from Cigna, WSJ reports »

New York Life Insurance…

CI

Cigna

$190.30

-5.59 (-2.85%)

MET

MetLife

$49.25

-0.315 (-0.64%)

SLF

Sun Life Financial

$44.95

0.465 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Feb

  • 13

    Feb

UPWK

Upwork

$10.60

-0.55 (-4.93%)

13:25
12/10/19
12/10
13:25
12/10/19
13:25
Options
Upwork call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.